Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acurx PharmaceuticalsACXP +0.70%37 Equity-to-Asset is 0.74 as of Jun. 2026, which is 6% above its 10-year median of 0.70. GuruFocus rates ACXP with a GF Score™ of 37/100. Among 1,414 Biotechnology companies, Acurx Pharmaceuticals ranks better than 57.64% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Acurx Pharmaceuticals Equity-to-Asset Related Terms
Acurx Pharmaceuticals Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Acurx Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACXP vs ENVB, HCWB, AAGH: Equity-to-Asset Comparison
For the Biotechnology subindustry, Acurx Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acurx Pharmaceuticals Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acurx Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Acurx Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Acurx Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acurx Pharmaceuticals (ACXP) has a Equity-to-Asset of 0.74 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Acurx Pharmaceuticals and its competitors. This is near median its historical median of 0.70. Over the past decade, Acurx Pharmaceuticals' Equity-to-Asset has ranged from 0.16 to 0.95. According to the industry distribution chart, Acurx Pharmaceuticals ranks #599 out of 1414 companies in the Biotechnology industry, placing it in the top 42.4%.
Is Acurx Pharmaceuticals' Equity-to-Asset too high?
Acurx Pharmaceuticals' current Equity-to-Asset of 0.74 is near median its 10-year median of 0.70. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 0.95. The Biotechnology industry median Equity-to-Asset is 0.68. Acurx Pharmaceuticals' value of 0.74 is 8.8% above this industry median. Based on the distribution chart, Acurx Pharmaceuticals ranks #599 out of 1414 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Acurx Pharmaceuticals has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Acurx Pharmaceuticals' Equity-to-Asset compare to ENVB and HCWB?
According to the Biotechnology industry distribution chart, Acurx Pharmaceuticals ranks #599 out of 1414 companies for Equity-to-Asset. This puts Acurx Pharmaceuticals in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Acurx Pharmaceuticals' value of 0.74 is 8.8% above this benchmark. Historically, Acurx Pharmaceuticals' own Equity-to-Asset has ranged from 0.16 to 0.95 over the past decade. While the company's 10-year median is 0.70 vs. the industry median of 0.68, Acurx Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acurx Pharmaceuticals's current Equity-to-Asset of 0.74 is 8.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Acurx Pharmaceuticals and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acurx Pharmaceuticals's current Equity-to-Asset is 0.74, which is near median its own 10-year median of 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acurx Pharmaceuticals stock overvalued right now?
Acurx Pharmaceuticals (ACXP) has a current Equity-to-Asset of 0.74. The current Equity-to-Asset is 0.74, which is near median its 10-year median of 0.70 and 8.8% above the Biotechnology industry median of 0.68. Acurx Pharmaceuticals' overall GF Score™ is 37/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Acurx Pharmaceuticals (ACXP), the current Equity-to-Asset is 0.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
37GF Score
Get the complete analysis for ACXP
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACXP has been successfully added to your 
